Laboratorio Clinico Montellano

Summary Statement of Deficiencies D0000 An offsite Proficiency Test (PT) Desk Review was performed on February 3, 2026 to Laboratorio Clinico Montellano, the laboratory was found out of compliance with the following conditions: 42 CFR 493.803 Proficiency Testing, Successful Participation 42 CFR 493.1403 Laboratory Director, Moderate complexity D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: A. Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of two (2) consecutive testing events in the analyte Sodium for Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- the subspecialty of routine chemistry tests. Refer to D2096. B.Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of two (2) consecutive testing events for the subspecialty of endocrinology tests. Refer to D2107. D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of two (2) consecutive testing events in the Sodium analyte for the subspecialty of routine chemistry tests. The findings include: 1. Review of the Casper Report 0155D and PRPTSP scores on January 26, 2026, confirmed that the laboratory had a PT (Proficiency Test) failure in the Sodium analyte for the subspecialty of routine chemistry tests. The laboratory obtained the following testing scores: Analyte: Sodium a. Second testing event year 2025 - 60% b. Third testing event year 2025 - 0% 2. A review of the PRPTSP records confirmed the above findings. D2107 ENDOCRINOLOGY CFR(s): 493.843(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of two (2) consecutive testing events for the subspecialty of endocrinology tests. The findings include: 1. Review of the Casper Report 0155D and PRPTSP scores on Janary 26, 2026, confirmed that the laboratory had a PT (Proficiency Test) failure for the subspecialty of endocrinology. The laboratory obtained the following testing scores: Analyte: Endocrinology a. First testing event year 2025 - 50% b. Third testing event year 2025 - 0% 2. A review of the PRPTSP records confirmed the above findings. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. -- 2 of 3 -- This CONDITION is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory director failed to provide overall management and direction samples were tested as required. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) (year 2025), the laboratory director failed to ensure successful participation in an HHS-approved proficiency testing program. Refer to D2096 and D2107. -- 3 of 3 --

Summary Statement of Deficiencies D5405 PROCEDURE MANUAL CFR(s): 493.1251(c) Manufacturer's test system instructions or operator manuals may be used, when applicable, to meet the requirements of paragraphs (b)(1) through (b)(12) of this section. Any of the items under paragraphs (b)(1) through (b)(12) of this section not provided by the manufacturer must be provided by the laboratory. This STANDARD is not met as evidenced by: Based on Immuno Card Mycoplasma manufacturer's instructions, General Immunology (Mycoplasma pneumoniae) testing record review from August 1, 2021 to August 31, 2021 and interview with the laboratory supervisor on December 2, 2021 at 10:20 AM, it was determined that the laboratory failed to follow the manufacturer's instruction when 131 out of 131 patients specimens were tested and reported for of Mycoplasma pneumoniae from August 1, 2021 to August 31, 2021. The findings include: 1. The laboratory use the Immuno Card Mycoplasma Test Cassette to perform the Mycoplasma pneumoniae qualitative tests. 2. The manufacturer's instruction establishes to perform the test procedures at room temperature range from 22 to 25 C. 3. On December 2, 2021 at 10:20 AM, review of the Mycoplasma pneumoniae testing records showed that the laboratory did not monitor or document the room temperature when patient's specimens were tested for Mycoplasma by Immuno Card Meridian method from from August 1, 2021 to August 31, 2021. 4. The laboratory supervisor confirmed on December 2, 2021 at 10:30 AM, that the laboratory did not monitor or document the room temperature when it processed the patients specimens for Mycoplasma pneumoniae test. 5. The laboratory processed and reported 131 patient samples for Mycoplasma pneumoniae test from August 1, 2021 to August 31, 2021. D6079 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(a)(b) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, record and report test results promptly, accurately and proficiently, and for assuring compliance with the applicable regulations. (a) The laboratory director, if qualified, may perform the duties of the technical supervisor, clinical consultant, general supervisor, and testing personnel, or delegate these responsibilities to personnel meeting the qualifications under 493.1447, 493.1453, 493.1459, and 493.1487 respectively. (b) If the laboratory director reapportions performance of his or her responsibilities, he or she remains responsible for ensuring that all duties are properly performed. This STANDARD is not met as evidenced by: Based on Immuno Card Mycoplasma manufacturer's instructions, Mycoplasma testing records and laboratory supervisor interview on December 2, 2021 at 10:20 AM, it was determined that the laboratory director did not fulfill her responsibilities to ensure that the that the laboratory did not follow the manufacture's instructions for the temperature of processing from August 1, 2021 to August 31, 2021. Refer D5405. -- 2 of 2 --

Summary Statement of Deficiencies D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (1)(i)(A) Accuracy. (1)(i) (B) Precision. (1)(i)(C) Reportable range of test results for the test system. (1)(ii) Verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population. This STANDARD is not met as evidenced by: 1. Based on review of validation records of the DxC 700au system and technical supervisor interview at 10:50 am on November 8, 2019, it was determined that the laboratory failed to verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population before reporting 81,107 routine chemistry patient tests results from May 1, 2019 to November 7, 2019. The findings included: a. On November 8, 2019 at 10:50 AM, the validation records of the DxC 700au system showed that the laboratory performed the validation procedures on April 24, 2019. However, the laboratory did not verify that the manufacturer's normal values of the routine chemistry tests are appropriate for the laboratory's patient population before reporting patient results from May 1, 2019 to November 7, 2019. b. The supervisor interview confirmed at 10:50 am on November 8, 2019 , that the laboratory did not verify that the manufacturer's reference intervals (normal values) before reporting routine chemistry patients tests results. c. The laboratory processed and reported 81,107 routine chemistry tests from May 1, 2019 to November 7, 2019 by the DxC 700au system. 2. Based on review of validation records of the Act 5 Diff system and technical supervisor interview at 11:10 am on November 8, 2019, it was determined that the laboratory failed to verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population before Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- reporting complete blood cell (CBC) patient results during year 2018. The findings included: a. On November 8, 2019 at 11:10 AM, the validation records of the Act 5 diff system showed that the laboratory performed the validation procedures on December 6, 2017. However, the laboratory did not verify that the manufacturer's normal values of the CBC tests are appropriate for the laboratory's patient population before reporting 40,696 CBC tests results during year 2018. b. The supervisor interview confirmed at 11:10 am on November 8, 2019, that the laboratory did not verify that the manufacturer's reference intervals (normal values) before reporting patients CBC results. c. The laboratory processed and reported 40,696 CBC tests during year 2018. D5445 CONTROL PROCEDURES CFR(s): 493.1256(d)(1)(2)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- (d)(1) Perform control procedures as defined in this section unless otherwise specified in the additional specialty and subspecialty requirements at 493.1261 through 493.1278. (d)(2) For each test system, perform control procedures using the number and frequency specified by the manufacturer or established by the laboratory when they meet or exceed the requirements in paragraph (d)(3) of this section. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on review of Individualized Quality Control Plan (IQCP) in Bacteriology and interview with the technical supervisor at 12:40 PM on November 8, 2019, the laboratory failed to develop complete IQCP for the Microscan Identification system and Antimicrobial Sensitivity test. The findings include: 1. The IQCP for the Microscan Identification system and Antimicrobial Sensitivity test did not include the following requirements: a. The Risk Assessment (RA) information (potential failure modes, possible failure cause, estimate the probability that the failures would occur and estimate the probability would lead to a hazardous situation). b. The Quality Control Plan (QCP) did not have the approval signature of the laboratory director. c. The Quality Assessment (QA) section was not included. 2. The technical supervisor confirmed at 12:40 PM on November 8, 2019, the laboratory failed to develop complete IQCP for the Microscan Identification system and Antimicrobial Sensitivity test. 3. The laboratory processed 1,336 patients specimens in the Bacteriology area during the year 2018. D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality control programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on review of Individualized Quality Control Plan (IQCP) in Bacteriology, validation records of the DxC 700au system and the Act 5 Diff system, and interview with the technical supervisor at 12:40 PM on November 8, 2019, the laboratory director failed to comply with requirements of the quality control programs in the -- 2 of 3 -- following specialties: Bacteriology, Routine chemistry and Hematology. Refer to D 5421 (1) (2) ( The laboratory failed to verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population before reporting routine chemistry and CBC patient results). Refer to D 5445 (The laboratory failed to develop complete IQCP for the Microscan Identification system and Antimicrobial Sensitivity test). D6117 TECHNICAL SUPERVISOR RESPONSIBILITIES CFR(s): 493.1451(b)(4) The technical supervisor is responsible for establishing a quality control program appropriate for the testing performed and establishing the parameters for acceptable levels of analytic performance and ensuring that these levels are maintained throughout the entire testing process from the initial receipt of the specimen, through sample analysis and reporting of test results. This STANDARD is not met as evidenced by: Based on review of validation records of the DxC 700au system and the Act 5 Diff system, and interview with the technical supervisor at 11:10 AM on November 8, 2019, the technical superviosr failed to comply with the requirements for analytic systems. Refer to D 5421 (1) (2) ( The laboratory failed to verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population before reporting routine chemistry and CBC patient results). -- 3 of 3 --